A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
Aged
Anti-Inflammatory Agents, Non-Steroidal
/ therapeutic use
Disease Progression
Female
Humans
Idiopathic Pulmonary Fibrosis
/ drug therapy
Lung
/ physiopathology
Lung Transplantation
/ statistics & numerical data
Male
Medication Adherence
/ statistics & numerical data
Middle Aged
Poland
Pyridones
/ therapeutic use
Respiratory Function Tests
Retrospective Studies
Treatment Outcome
Walk Test
Efficacy
Idiopathic pulmonary fibrosis
Pirfenidone
Poland
Real-world data
Safety
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
04 May 2020
04 May 2020
Historique:
received:
07
02
2020
accepted:
20
04
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
26
1
2021
Statut:
epublish
Résumé
Pirfenidone is an antifibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF). The drug is available for Polish patients with IPF since 2017. The PolExPIR study aimed to describe the real-world data (RWD) on the Polish experience of pirfenidone therapy in IPF with respect to safety and efficacy profiles. This was a multicentre, retrospective, observational study collecting clinical data of patients with IPF receiving pirfenidone from January 2017 to September 2019 across 10 specialized pulmonary centres in Poland. Data collection included baseline characteristics, pulmonary function tests (PFTs) results and six-minute walk test (6MWT). Longitudinal data on PFTs, 6MWT, adverse drug reactions (ADRs), treatment persistence, and survival were also collected up to 24 months post-inclusion. A total of 307 patients receiving pirfenidone were identified for analysis. The mean age was 68.83 (8.13) years and 77% were males. The median time from the first symptoms to IPF diagnosis was 15.5 (9.75-30) months and from diagnosis to start of pirfenidone treatment was 6 (2-23) months. Patients were followed on treatment for a median of 17 (12-22.75) months. Seventy-four patients (24.1%) required dose adjustments and 35 (11.4%) were chronically treated with different than the full recommended dose. A total of 141 patients (45.92%) discontinued therapy due to different reasons including ADRs (16.61%), death (8.79%), disease progression (6.51%), patient's own request (5.54%), neoplastic disease (3.91%) and lung transplantation (0.33%). Over up to 24 months of follow-up, the pulmonary function remained largely stable. The median annual decline in forced vital capacity (FVC) during the first year of pirfenidone therapy was -20 ml (-200-100) and during the second year was -120 ml (-340-30). Over a study period, 33 patients (10.75%) died. The PolExPIR study is a source of longitudinal RWD on pirfenidone therapy in the Polish cohort of patients with IPF supporting its long-term acceptable safety and efficacy profiles and reinforce findings from the previous randomised clinical trials and observational studies.
Sections du résumé
BACKGROUND
BACKGROUND
Pirfenidone is an antifibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF). The drug is available for Polish patients with IPF since 2017. The PolExPIR study aimed to describe the real-world data (RWD) on the Polish experience of pirfenidone therapy in IPF with respect to safety and efficacy profiles.
METHODS
METHODS
This was a multicentre, retrospective, observational study collecting clinical data of patients with IPF receiving pirfenidone from January 2017 to September 2019 across 10 specialized pulmonary centres in Poland. Data collection included baseline characteristics, pulmonary function tests (PFTs) results and six-minute walk test (6MWT). Longitudinal data on PFTs, 6MWT, adverse drug reactions (ADRs), treatment persistence, and survival were also collected up to 24 months post-inclusion.
RESULTS
RESULTS
A total of 307 patients receiving pirfenidone were identified for analysis. The mean age was 68.83 (8.13) years and 77% were males. The median time from the first symptoms to IPF diagnosis was 15.5 (9.75-30) months and from diagnosis to start of pirfenidone treatment was 6 (2-23) months. Patients were followed on treatment for a median of 17 (12-22.75) months. Seventy-four patients (24.1%) required dose adjustments and 35 (11.4%) were chronically treated with different than the full recommended dose. A total of 141 patients (45.92%) discontinued therapy due to different reasons including ADRs (16.61%), death (8.79%), disease progression (6.51%), patient's own request (5.54%), neoplastic disease (3.91%) and lung transplantation (0.33%). Over up to 24 months of follow-up, the pulmonary function remained largely stable. The median annual decline in forced vital capacity (FVC) during the first year of pirfenidone therapy was -20 ml (-200-100) and during the second year was -120 ml (-340-30). Over a study period, 33 patients (10.75%) died.
CONCLUSIONS
CONCLUSIONS
The PolExPIR study is a source of longitudinal RWD on pirfenidone therapy in the Polish cohort of patients with IPF supporting its long-term acceptable safety and efficacy profiles and reinforce findings from the previous randomised clinical trials and observational studies.
Identifiants
pubmed: 32366291
doi: 10.1186/s12890-020-1162-6
pii: 10.1186/s12890-020-1162-6
pmc: PMC7199354
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Pyridones
0
pirfenidone
D7NLD2JX7U
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
122Références
Respirology. 2014 Jul;19(5):740-7
pubmed: 24836849
Adv Ther. 2019 May;36(5):1126-1131
pubmed: 30900199
Respiration. 2014;88(3):199-207
pubmed: 25115833
N Engl J Med. 2018 May 10;378(19):1811-1823
pubmed: 29742380
BMC Pulm Med. 2018 Nov 23;18(1):177
pubmed: 30470213
J Clin Med. 2016 Sep 02;5(9):
pubmed: 27598213
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620906326
pubmed: 32066332
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Eur Clin Respir J. 2016 Sep 09;3:32608
pubmed: 27616539
Eur Respir J. 2010 Apr;35(4):821-9
pubmed: 19996196
Respir Med. 2015 Jul;109(7):904-13
pubmed: 25962649
Respiration. 2019;98(1):19-28
pubmed: 30965332
Arch Bronconeumol. 2019 Feb;55(2):75-80
pubmed: 30049557
Adv Respir Med. 2017;85(3):136-142
pubmed: 28667654
N Engl J Med. 2014 May 29;370(22):2083-92
pubmed: 24836312
Eur Respir J. 2016 Jan;47(1):243-53
pubmed: 26647432
BMC Pulm Med. 2018 May 11;18(1):69
pubmed: 29751748
Adv Ther. 2015 Jul;32(7):691-704
pubmed: 26173796
Eur Respir Rev. 2015 Mar;24(135):58-64
pubmed: 25726556
Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40
pubmed: 20935110
Respir Med. 2013 Sep;107(9):1431-7
pubmed: 23849626
Ann Intern Med. 2012 May 15;156(10):684-91
pubmed: 22586007
Front Pharmacol. 2018 Dec 17;9:1480
pubmed: 30618768
Eur Clin Respir J. 2016 Jul 18;3:32035
pubmed: 27435431
Respir Med. 2019 Sep;156:78-84
pubmed: 31445389
Eur Respir J. 2017 Sep 11;50(3):
pubmed: 28893868
Adv Respir Med. 2019;87(6):221-230
pubmed: 31970724
Lancet. 2011 May 21;377(9779):1760-9
pubmed: 21571362
Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19
pubmed: 26177183
BMJ Open Respir Res. 2016 Jan 12;3(1):e000105
pubmed: 26835133
Intern Med. 2016;55(5):443-8
pubmed: 26935361
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Respir Res. 2019 Jan 21;20(1):16
pubmed: 30665416
Front Med (Lausanne). 2017 Nov 29;4:213
pubmed: 29238708
Respir Res. 2019 Oct 24;20(1):231
pubmed: 31651324
Respir Med. 2014 Jan;108(1):224-6
pubmed: 24269005
ERJ Open Res. 2018 Oct 19;4(4):
pubmed: 30364407